Clinical Trial Update: Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating systemic VEGF protein dynamics after intravitreal ranibizumab versus aflibercept in patients with diabetic macular edema has been withd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Visual Impairment Due to Diabetic Macular Edema | Phase 4 | Status: WITHDRAWN